Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval is an ...

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The short answer is no, you cannot outgrow asthma, but your symptoms may be less severe. Learn when asthma goes into ...

Breathing is essential for life, yet for many individuals suffering from chronic respiratory issues such as asthma and COPD, ...

A small proportion of veterans who went from a metered-dose inhaler to a dry-powder inhaler had to revert to the metered-dose ...